By Nigam Arora & Dr. Natasha Arora
Intelligence to prepare you in advance to act advantageously when a signal to act arrives.
Lucrative Opportunities
Lucrative opportunities are ahead in personalized cancer vaccines.
Several ideas are on our radar at The Arora Report.
Cancer Vaccines Are Different
A cancer vaccine is different than the types of vaccines that are currently available. Existing vaccines aim to prevent infections. This new class of cancer vaccines aims to treat a disease that a patient already has.
Milestone
Please click here for a chart of Moderna (MRNA).
Note the following:
- The chart shows when Moderna announced a new milestone in personalized cancer vaccines.
- The chart shows a large move up in the stock.
- Moderna and Merck announced promising top-line Phase 2b clinical trial data showing efficacy for stage III/IV melanoma. The results have significant implications for the future of cancer treatments.
- The way the combination treatment from Merck and Moderna works is that KEYTRUDA amps up the body’s immune response to fight the cancer cells, and the cancer vaccine helps guide the immune cells to the cancer cells.
- The combination of Merck’s anti-PD-1 therapy KEYTRUDA and Moderna’s personalized mRNA cancer vaccine, compared to KEYTRUDA alone, reduced the risk of recurrence or death by 44% in patients with complete resection of stage III/IV melanoma who were at high risk for recurrence. The results must still be reviewed by an independent panel.
- Moderna and Merck are planning to begin a Phase 3 clinical trial in 2023 and are looking to quickly begin trials in other types of cancer. Given Merck’s strength in oncology, this could be very productive and profitable.
- Both companies will benefit from Moderna’s cancer vaccine mRNA-4157/V940 as Merck exercised the option for joint development and commercialization.
- If you are interested in a podcast on cancer vaccines, please write to Ambassador@TheAroraReport.com.
Model Portfolio
Depending on the progress in the Phase 3 clinical trial, Moderna is on the list to potentially be added to the Model Portfolio.
Zones
In due course, the plan is to provide buy zone, target zone, and stop zone. Of course, it will all depend on a complex set of criteria.
Stay tuned.
To take a free 30-day trial to paid services to gain access to more opportunities, please click here.
This post was just published on ZYX Buy Change Alert.
Markets can generate substantial wealth for knowledgeable investors. NOW YOU TOO CAN ALSO SPECTACULARLY SUCCEED AT MEETING YOUR GOALS WITH THE HELP OF THE ARORA REPORT. You are receiving less than 2% of the content from our paid services. …TO RECEIVE REMAINING 98% INCLUDING MANY ATTRACTIVE INVESTMENT OPPORTUNITIES, TAKE A FREE
TRIAL TO PAID SERVICES.
Please click here to take advantage of a FREE 30 day trial.
Nigam Arora
Nigam Arora is known for his accurate stock market calls. Nigam is a distinguished master of the macro. He is a popular columnist with over 100 million page views, an engineer, and nuclear physicist by background. Nigam has founded two Inc. 500 fastest growing companies and has been involved in over 50 entrepreneurial ventures. He is the developer of Theory ZYX of Successful Change Management and is the author of the book on Theory ZYX, as well as the developer of the ZYX Change Method for Investing.
Dr. Natasha Arora
Dr. Natasha Arora has significant expertise in investment analysis especially biotech, healthcare, and technology. Natasha is a graduate of Harvard Medical School followed by a postdoc at MIT. She has published several peer reviewed research papers in top science journals.
